Larimar Therapeutics (LRMR) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 18.3% versus a loss of 41.7%. Over five years, LRMR leads with a -77.3% price change compared with -98.2% for XFOR. Larimar Therapeutics is the larger company by market cap ($280.5 million vs $276.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | XFOR |
|---|---|---|
| Share price | $2.70 | $2.79 |
| Market cap | $280.48M | $276.62M |
| 1-day change | -1.82% | -0.71% |
| YTD return | -27.82% | -29.75% |
| 1-year return | -41.74% | -18.31% |
| 5-year return | -77.31% | -98.21% |
| P/E ratio (TTM) | — | 139.50 |
| EPS (TTM) | $-1.99 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $4.83 |
| 52-week low | $2.61 | $2.70 |
| Distance from 52-week high | -57.94% | -42.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +433.33% | +315.77% |
| Average volume | 1.31M | 843.50K |
| Shares outstanding | 103.88M | 99.15M |
| Employees | 71 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XFOR has outperformed LRMR by 23.4 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
LRMR vs XFOR FAQ
Which is bigger, Larimar Therapeutics or X4 Pharmaceuticals?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $280.48M compared with $276.62M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, LRMR or XFOR?
XFOR returned -18.31% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and X4 Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Larimar Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for X4 Pharmaceuticals.